Retrolaminar Block for Pediatric Thoracoscopic Sympathectomy

March 16, 2023 updated by: Mahmoud Mohammed Alseoudy, Mansoura University

Ultrasound-guided Retrolaminar Block Versus Paravertebral Block for Postoperative Analgesia in Children Undergoing Thoracoscopic Sympathectomy: a Non-inferiority Study

Thoracoscopic sympathectomy is a rapid and simple technique associated with rare complications, but it is associated with severe postoperative pain that makes breathing and coughing difficult resulting in increased occurrence of pulmonary complications. Paravertebral block has frequently been performed for this procedure but its technical difficulty and safety profile may represent a limitation of its routine use. This prospective, randomized, double-blind controlled study is designed to compare the postoperative analgesic efficacy of ultrasound-guided thoracic retrolaminar block (TRLB) with the paravertebral block in children undergoing thoracoscopic sympathectomy. We hypothesize that ultrasound-guided thoracic retrolaminar block may comparable analgesic effect to paravertebral block with a lesser incidence of complications in pediatric patients undergoing thoracoscopic sympathectomy.

Study Overview

Detailed Description

Thoracoscopic sympathectomy is a rapid and simple technique associated with rare complications, but it is associated with severe postoperative pain that makes breathing and coughing difficult resulting in increased occurrence of pulmonary complications, need for analgesic, and hospital stays. Postoperative pain control for pediatric surgeries is a major issue and affects the quality of recovery, parental satisfaction, and surgical success. Opioid usage for pediatric analgesia has many disadvantages, such as postoperative vomiting, pruritus, respiratory depression, and sedation. The introduction of anatomy-based ultrasound (US) imaging for facilitating nerve localization is a major advancement in the field of pediatric regional anesthesia. Paravertebral block has frequently been performed for this procedure but its technical difficulty and safety profile may represent a limitation of its routine use. Ultrasound-guided retrolaminar block (RLB) is a newer alternative to PV block where LA is injected between the lamina and deep paraspinal muscle, rather than between the parietal pleura and costotransverse ligament. This makes it both technically less difficult, but also at less risk of causing substantial side effects such as pneumothorax, inadvertent intrathecal injection, and neurological injury. The analgesic efficacy of RLB has been proven in adults after breast surgery, in patients with multiple rib fractures, and after acute lumbar trauma. This prospective, randomized, double-blind controlled study is designed to compare the postoperative analgesic efficacy of ultrasound-guided thoracic retrolaminar block (TRLB) with the paravertebral block in children undergoing thoracoscopic sympathectomy. We hypothesize that ultrasound-guided thoracic retrolaminar block may comparable analgesic effect to paravertebral block with a lesser incidence of complications in pediatric patients undergoing thoracoscopic sympathectomy. The study will be carried out in Mansoura university children's hospital (MUCH) after obtaining approval from Mansoura Faculty of Medicine Institutional Research Board. Informed written consent will be obtained from the patient guardians'. The planned duration of this study is 8 months. The time gap of the study will be from January 2021 to August 2020.

Eighty children of the American Society of Anesthesiologists physical status I-II of either sex with their age ranging from 8 to 18 years undergoing thoracoscopic surgeries will be recruited for the study.Exclusion criteria will include the history of clinically significant cardiac, hepatic, renal, or neurological dysfunction, coagulopathy, known allergy to amide local anesthetics, and local infection at injection sites.General anesthesia will be induced with incremental sevoflurane in 100% oxygen. After reaching an adequate depth of anesthesia, venous access was established, and then vecuronium will be given in a dose of 0.6 mg/kg and ETT will be inserted. Anesthesia was maintained under controlled ventilation with 1-1.5 MAC of isoflurane and 0.1 mg/kg vecuronium every 30 minutes as a muscle relaxant. Standard intraoperative monitors will be applied for measurement of ECG, heart rate, pulse oximetry, noninvasive blood pressure, and end-tidal carbon dioxide concentration. Baseline readings will be recorded.Computer-generated random numbering of the studied patients will be used for patient randomization before surgery. An opaque sealed envelope will be used and opened in the operative theatre by an anesthesiologist who will not be involved in the current study and who will prepare the drugs used in the study. The anesthesiologist who will be responsible for the patient and the nurse who recorded the patient data will be unaware of the patient's group. Patients will be randomly allocated to one of two equal groups (40 patients for each). Control group (n=40): the patients will receive paravertebral. block.TRLB block group (n=40): ultrasound-guided thoracic retrolaminar block (TRLB).All blocks will be performed by the same anesthetist who is experienced in US-guided pediatric nerve blocks. A high-resolution linear probe with a sterile cover will be used to perform the block. All surgical procedures will be performed by the same surgical team.All blocks will be performed by the same anesthetist who is experienced in US-guided pediatric nerve blocks... All surgical procedures will be performed by the same surgical team.The patient will be placed in a prone position with a pillow under the chest. The spinous process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high-frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vertebral lamina. An 80 mm 22-gauge needle will be inserted in an in-plane technique from cranial to the caudal direction and will be advanced till hitting the laminae of the fourth thoracic vertebrae and then we will try to inject the local anesthetic between the lamina and deep paraspinal muscle in RLB group and between the parietal pleura and costotransverse ligament in the paravertebral group. . Bupivacaine 0.25%, 0.4mL/kg will be injected. Vital signs will be recorded every 5 min after the block to ensure the adequacy of the blockade, especially after surgical incision. Surgical procedures will be allowed to start 15 min after the performance of the block. In case of an increase in either patient heart rate to more than 20% of the baseline, fentanyl at 1 ug/kg will be administered. More than 30% decrease in heart rate and systolic blood pressure, respectively, as compared with the baseline values will be treated with atropine or ephedrine as appropriate but the postoperative data of those patients will not be included in the statistical analysis.After completion of the surgery, children will be transferred to the post-anesthesia care unit (PACU) for continuous monitoring of vital signs and for pain assessment. Children will be monitored every 15 min during the first hour in the PACU and every 30 min in the daycare unit until discharge from the hospital. Postoperative analgesia will be measured using vas score 0, 1, 2, 4, 6, 12, 18, 24 hours after surgery. Patients with vas>3 will be given rescue analgesia with 0.05mg/kg morphine intravenously. The primary outcome measure is the total morphine consumption in the first postoperative 24 h. The secondary outcome measures are Postoperative pain score, Time to first rescue analgesia and its frequency, Parent's satisfaction. Block-related complications (pneumothorax, local anesthetic toxicity, or hematoma) and frequency of Nausea and vomiting. Data will be analyzed through SPSS (Statistical Package for Social Sciences). Program version 22. The distribution of data will be first tested by the Shapiro test. Data will be presented as mean and standard deviation (SD), median, and range of numbers and percentages. For normally distributed data, an unpaired t-test will be used to compare between mean values of both groups. For pain score, Mann Whitney U test will be used. Fisher's exact test will be used for comparison of categorical data. The P-value ≤ of 0.05 will be considered as the level of statistical significance.

Study Type

Interventional

Enrollment (Anticipated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Dakahlia
      • Mansoura, Dakahlia, Egypt, 35511
        • Recruiting
        • Department of Anesthesia, Mansoura University Hospitals
        • Contact:
        • Sub-Investigator:
          • Sameh M El-Sherbiny, MD
        • Principal Investigator:
          • Amany H El-Deeb, MSc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • American Society of Anesthesiologists (ASA) status: 1 or 2
  • thoracoscopic sympathectomy

Exclusion Criteria

  • history of clinically significant cardiac, hepatic, renal, or neurological dysfunction
  • coagulopathy
  • known allergy to amide local anesthetics
  • local infection at injection sites

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group A (Retrolamianar block(RLB))
Ultrasound-guided RLB with injection of 0.4ml/kglocal anesthestic (bupivacaine) 0.25%will be performed under strict aseptic precautions with ultrasound guidance with patient in the prone position.
A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The spinous process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vertebral lamina. A 50 mm 22-gauge needle will be inserted in an in-plane technique from cranial to caudal direction and will be advanced till hitting the laminae of fourth thoracic vertebrae and then we will try to inject the local anesthetic, if the resistance to injection is very high, hence we will withdraw the needle slowly and its tip will be kept in its position immediately after disappearance this high resistance. Bupivacaine 0.25%, 0.4mL/kg will be injected.
Active Comparator: Paravertebral group
Ultrasound-guided paravertebral injection of 0.4ml/kg saline 0.9% will be performed under strict aseptic precautions under ultrasound guidance with patient in the prone position.
A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The transverse process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vcostotransverse ligament, 0.4mL/kg will be injected

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
morphine consumption
Time Frame: Up to 24 hours after the procedure
The total dose of morphine consumed in first 24 hours will be recorded (mg)
Up to 24 hours after the procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pain score
Time Frame: Up to 24 hours after the procedure
Pain levels will be assessed post operatively using visual analogue scale(vas),usually 10 centimeters (100 mm) in length, For pain intensity, the scale is most commonly anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100 [100-mm scale]),vas measured at 0,1, 2, 4, 6, 12, 24 hours
Up to 24 hours after the procedure
number of patients who will need analgesia
Time Frame: Up to 24 hours after the procedure
number of patients who request analgesia in the postoperative period
Up to 24 hours after the procedure
Block related complications
Time Frame: Up to 24 hours after the procedure
Block related complications (pneumothorax, local anesthetic toxicity or hematoma).[
Up to 24 hours after the procedure
time of first analgesic request (min)
Time Frame: Up to 24 hours after the procedure
the time of first analgesic request in first 24 hours
Up to 24 hours after the procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 3, 2021

Primary Completion (Anticipated)

November 15, 2023

Study Completion (Anticipated)

December 20, 2023

Study Registration Dates

First Submitted

December 19, 2020

First Submitted That Met QC Criteria

December 25, 2020

First Posted (Actual)

December 30, 2020

Study Record Updates

Last Update Posted (Actual)

March 17, 2023

Last Update Submitted That Met QC Criteria

March 16, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • R.20.12.1115

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pediatric Thoracoscopy

Clinical Trials on Retrolaminar block

Subscribe